HomeOur ProjectsHepC in NYC

HepC in NYC

Overview:

Addressing HCV-related hepatocellular carcinoma: the current and future epidemics.” Hepatitis C virus (HCV)-related deaths now exceed HIV-related deaths in the US. Throughout the world, HCV is hyperendemic in people who inject drugs (PWID). New outbreaks of acute HCV infection are unfolding in HIV-positive men who have sex with men (MSM) and in 15-24 year olds who have transitioned from abuse of prescription opioids to illicit opiate injection. In patients with chronic HCV infection, 20-25% will develop liver disease which may manifest as cirrhosis, liver failure or hepatocellular carcinoma (HCC). The prognosis for HCC is extremely poor, and HCV is the chief etiologic agent for this type of cancer. Recent discoveries in HCV prevention and treatment provide a great opportunity to reverse the trend toward increasing rates of HCV, HCV/HIV co-infection, and HCC. This study will use the methods of Implementation Science – research synthesis, mathematical modeling and simulation, and comparative effectiveness analyses – to determine how best to constitute a portfolio of interventions for the prevention and control of HCV and its consequences while taking into account limited resources and underlying epidemiologic and social network features. A dissemination plan will make extensive use of technology, including social media, and guidance from key stakeholders.

Featured News
Latest News

Kirk Dombrowski, the principle investigator of the REACH Lab, recently published a research paper on how the War on Drugs is affecting people who inject drugs in rural Puerto Rico. This paper was published in the International Journal of Drug Policy. The War on Drugs has raised the incarceration rates of racial

Researchers in the lab recently published a paper examining serosorting habits in rural Puerto Rico. The paper was published in Preventive Medicine Reports earlier this year. Serosorting is using one’s own and questioning others’ HIV or HCV infection status to determine whether to engage in risk or not. In an

Researchers in the REACH Lab recently published a paper to the Journal of Ethnicity in Substance Abuse alongside employees from the Puerto Rico Department of Health to examine Rural/Urban differences in risk networks and the spread of HIV and Hepatitis C. Researchers examined injection drug use in San Juan and in four

REACH Lab researchers Bilal Khan and Kirk Dombrowski recently had a research paper accepted to the 10th EAI International Conference on Bio-inspired Information and Communications Technologies. Wireless communication is an increasingly ubiquitous and important aspect of the digital  ecosystem. The Internet of Things (IOT) has been growing rapidly with a population of 4+ billion devices

Project Details

Addressing HCV-related hepatocellular carcinoma: the current and future epidemics.” Hepatitis C virus (HCV)-related deaths now exceed HIV-related deaths in the US. Throughout the world, HCV is hyperendemic in people who inject drugs (PWID). New outbreaks of acute HCV infection are unfolding in HIV-positive men who have sex with men (MSM) and in 15-24 year olds who have transitioned from abuse of prescription opioids to illicit opiate injection. In patients with chronic HCV infection, 20-25% will develop liver disease which may manifest as cirrhosis, liver failure or hepatocellular carcinoma (HCC). The prognosis for HCC is extremely poor, and HCV is the chief etiologic agent for this type of cancer. Recent discoveries in HCV prevention and treatment provide a great opportunity to reverse the trend toward increasing rates of HCV, HCV/HIV co-infection, and HCC. This study will use the methods of Implementation Science – research synthesis, mathematical modeling and simulation, and comparative effectiveness analyses – to determine how best to constitute a portfolio of interventions for the prevention and control of HCV and its consequences while taking into account limited resources and underlying epidemiologic and social network features. A dissemination plan will make extensive use of technology, including social media, and guidance from key stakeholders.

“Addressing HCV-related hepatocellular carcinoma: the current and future epidemics” is funded by the National Institute of Drug Abuse, R01 DA034637-01 under the direction of Holly Hagan, Principal Investigator, New York University, from July 2013-June 2017.[

The leader of this work at REACH is Kirk Dombrowski, who will work closely with Bilal Khan, and Mohamed Saad at CUNY to implement the simulation portion of the project using the MABUSE platform.